Belinostat

Search with Google Search with Bing

Information
Drug Name
Belinostat
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
cancer UGT1A6 c.862-6799_862-6798insTATATATATATATA, UGT1A5 c.868-6799_868-6798insTATATATATATATA, UGT1A9 c.856-6799_856-6798insTATATATATATATA, UGT1A7 c.856-6799_856-6798insTATATATATATATA, UGT1A4 c.868-6799_868-6798insTATATATATATATA, UGT1A8 c.856-6799_856-6798insTATATATATATATA, UGT1A10 c.856-6799_856-6798insTATATATATATATA, UGT1A3 c.868-6799_868-6798insTATATATATATATA
( ENST00000344644.10, ENST00000373445.1, ENST00000373450.5, ENST00000373426.4, ENST00000305139.11, ENST00000373424.5, ENST00000406651.1, ENST00000373414.4, ENST00000354728.5, ENST00000373409.8, ENST00000305208.10, ENST00000482026.6 ) UGT1A6 c.862-6799_862-6798insTATATATATATATA, UGT1A5 c.868-6799_868-6798insTATATATATATATA, UGT1A9 c.856-6799_856-6798insTATATATATATATA, UGT1A7 c.856-6799_856-6798insTATATATATATATA, UGT1A4 c.868-6799_868-6798insTATATATATATATA, UGT1A8 c.856-6799_856-6798insTATATATATATATA, UGT1A10 c.856-6799_856-6798insTATATATATATATA, UGT1A3 c.868-6799_868-6798insTATATATATATATA
( ENST00000344644.10, ENST00000373445.1, ENST00000373450.5, ENST00000373426.4, ENST00000305139.11, ENST00000373424.5, ENST00000406651.1, ENST00000373414.4, ENST00000354728.5, ENST00000373409.8, ENST00000305208.10, ENST00000482026.6 ) 		A Predictive Supports Adverse Response Common Germline 5 26313268 Detail
cancer UGT1A1 UGT1A1*60 UGT1A1 UNKNOWN B Predictive Supports Adverse Response Common Germline 4 26313268 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
The FDA approved package insert for Belinostat rec... UGT1A1 UGT1A6 c.862-6799_862-6798insTATATATATATATA, UGT1A5 c.868-6799_868-6798insTATATATATATATA, UGT1A9 c.856-6799_856-6798insTATATATATATATA, UGT1A7 c.856-6799_856-6798insTATATATATATATA, UGT1A4 c.868-6799_868-6798insTATATATATATATA, UGT1A8 c.856-6799_856-6798insTATATATATATATA, UGT1A10 c.856-6799_856-6798insTATATATATATATA, UGT1A3 c.868-6799_868-6798insTATATATATATATA
( ENST00000344644.10, ENST00000373445.1, ENST00000373450.5, ENST00000373426.4, ENST00000305139.11, ENST00000373424.5, ENST00000406651.1, ENST00000373414.4, ENST00000354728.5, ENST00000373409.8, ENST00000305208.10, ENST00000482026.6 ) UGT1A6 c.862-6799_862-6798insTATATATATATATA, UGT1A5 c.868-6799_868-6798insTATATATATATATA, UGT1A9 c.856-6799_856-6798insTATATATATATATA, UGT1A7 c.856-6799_856-6798insTATATATATATATA, UGT1A4 c.868-6799_868-6798insTATATATATATATA, UGT1A8 c.856-6799_856-6798insTATATATATATATA, UGT1A10 c.856-6799_856-6798insTATATATATATATA, UGT1A3 c.868-6799_868-6798insTATATATATATATA
( ENST00000344644.10, ENST00000373445.1, ENST00000373450.5, ENST00000373426.4, ENST00000305139.11, ENST00000373424.5, ENST00000406651.1, ENST00000373414.4, ENST00000354728.5, ENST00000373409.8, ENST00000305208.10, ENST00000482026.6 ) 		Adverse Response true CIViC Evidence detail
In a phase 1 trial belinostat (400-800mg/m2/24h) w... UGT1A1 UGT1A1 UGT1A1*60 UGT1A1 UNKNOWN Adverse Response true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03772925 Active, not recruiting Phase 1 Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome June 20, 2019 July 1, 2024
NCT02137759 Active, not recruiting Phase 2 MRSI to Predict Response to RT/TMZ ± Belinostat in GBM May 7, 2014 August 15, 2024
NCT04340843 Active, not recruiting Phase 2 Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma September 8, 2020 January 1, 2025
NCT00321594 Completed Phase 1/Phase 2 Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery May 2006 October 2012
NCT00334789 Completed Phase 1 Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery June 12, 2006 March 29, 2018
NCT00348985 Completed Phase 1 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas March 2006
NCT00351975 Completed Phase 1 Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases June 2006 March 2013
NCT00357032 Completed Phase 2 PXD101 in Treating Patients With Acute Myeloid Leukemia May 2006 July 2010
NCT00357162 Completed Phase 2 Belinostat in Treating Patients With Myelodysplastic Syndromes May 2006 December 2010
NCT00413322 Completed Phase 1 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors September 2005 June 2008
NCT00421889 Completed Phase 1/Phase 2 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment August 2005 February 2009
NCT00865969 Completed Phase 2 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma December 15, 2008 October 27, 2014
NCT00926640 Completed Phase 1 A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers July 1, 2009 April 20, 2018
NCT00993616 Completed Phase 2 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin December 2009 July 29, 2012
NCT01075425 Completed Phase 1 Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome May 2010 February 2015
NCT01273155 Completed Phase 1 Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction January 10, 2011 October 25, 2017
NCT01583777 Completed Phase 1 Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer September 2013 April 2015
NCT01686165 Completed Phase 2 Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL August 31, 2012 November 9, 2017
NCT01839097 Completed Phase 1 Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) May 2013 January 2016
NCT02142530 Completed Phase 1 Carfilzomib Plus Belinostat in Relapsed/Refractory NHL October 2014 January 2018
NCT00365053 Completed Phase 2 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery June 2006 March 2009
NCT00301756 Completed Phase 2 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors September 2006 December 2012
NCT00303953 Completed Phase 2 PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma January 2006 August 2010
NCT04184869 Completed Phase 1 Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials August 5, 2019 March 31, 2023
NCT06406465 Not yet recruiting Phase 2 A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity June 23, 2024 July 30, 2028
NCT02737046 Recruiting Phase 2 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma December 12, 2016 December 31, 2025
NCT05627245 Recruiting Phase 1 Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment March 1, 2023 March 1, 2025
NCT04747236 Recruiting Phase 2 Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL February 19, 2021 June 2, 2028
NCT04703920 Recruiting Phase 1 Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer March 4, 2021 July 2024
NCT05170334 Recruiting Phase 2 Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma December 15, 2021 December 2024
NCT04315233 Recruiting Phase 1 Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics May 3, 2021 August 2026
NCT05154994 Suspended Phase 1 Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma January 14, 2022 November 30, 2026
NCT03432741 Suspended Phase 1 Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer March 27, 2018 May 1, 2026
NCT00274651 Terminated Phase 2 A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas January 2006 July 2009
NCT00354185 Terminated Phase 1 PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma May 2006
NCT02679131 Terminated Phase 1 To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. March 2016 June 2017
NCT02381548 Terminated Phase 1 Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia August 18, 2015 May 23, 2018
NCT04315155 Withdrawn Phase 1 Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation October 2020 September 2025
NCT02701673 Withdrawn Phase 1/Phase 2 Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma June 2016
NCT02875002 Withdrawn Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas October 2016 September 2018
NCT02532192 Withdrawn Phase 1 A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma December 2015